Redx Pharma (AIM:REDX) - Hisse Senedi Fiyatı, Haberler ve Analizler

REDX Stoklara Genel Bakış

Engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. Daha fazla detay

REDX temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 22.3% oranında düşmesi öngörülüyor

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Hissedarlar geçen yıl sulandırıldı

+ 1 daha fazla risk

Redx Pharma Plc Rakipler

ECO Animal Health Group

AIM:EAH

UK£44.7m

Animalcare Group

AIM:ANCR

UK£148.5m

Alliance Pharma

AIM:APH

UK£246.0m

Allergy Therapeutics

AIM:AGY

UK£243.6m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Redx Pharma
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	UK£0.15
52 Haftanın En Yüksek Seviyesi	UK£0.38
52 Haftanın En Düşük Seviyesi	UK£0.04
Beta	-0.53
11 Aylık Değişim	-18.92%
3 Aylık Değişim	-25.00%
1 Yıllık Değişim	-53.85%
33 Yıllık Değişim	-76.92%
5 Yıllık Değişim	185.71%
Halka arzdan bu yana değişim	-82.46%

Son Haberler & Güncellemeler

Recent updates

Does Redx Pharma (LON:REDX) Have A Healthy Balance Sheet?

Aug 22

Is Redx Pharma (LON:REDX) Using Too Much Debt?

May 22

Bullish: Analysts Just Made A Significant Upgrade To Their Redx Pharma Plc (LON:REDX) Forecasts

Jul 09

Hissedar Getirileri

	REDX	GB Pharmaceuticals	GB Pazar
7D	62.2%	4.5%	2.2%
1Y	-53.8%	0.7%	8.0%

Getiri vs. Endüstri: REDX geçen yıl % 0.7 oranında getiri sağlayan UK Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: REDX geçen yıl % 8 oranında getiri sağlayan UK Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is REDX's price volatile compared to industry and market?
REDX volatility
REDX Average Weekly Movement	33.2%
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

İstikrarlı Hisse Senedi Fiyatı: REDX hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: REDX 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 17% dan 33% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2010	101	Lisa Mary Anson	www.redxpharma.com

Redx Pharma Plc Temel Bilgiler Özeti

Redx Pharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
REDX temel i̇stati̇sti̇kler
Piyasa değeri	UK£58.35m
Kazançlar(TTM)	-UK£33.16m
Gelir(TTM)	UK£4.20m

13.9x

P/S Oranı

-1.8x

F/K Oranı

REDX aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
REDX gelir tablosu (TTM)
Gelir	UK£4.20m
Gelir Maliyeti	UK£0
Brüt Kâr	UK£4.20m
Diğer Giderler	UK£37.36m
Kazançlar	-UK£33.16m

Son Raporlanan Kazançlar

Sep 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.085
Brüt Marj	100.00%
Net Kâr Marjı	-789.05%
Borç/Özkaynak Oranı	468.9%

REDX uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

REDX Stoklara Genel Bakış

Risk Analizi

Redx Pharma Plc Rakipler

AIM:EAH

UK£44.7m

AIM:ANCR

UK£148.5m

AIM:APH

UK£246.0m

AIM:AGY

UK£243.6m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Redx Pharma Plc Reports Encouraging Zamaporvint (RXC004) Phase 2 Combination Data in MSS mCRC at ESMO GI Congress

Redx to Present Zamaporvint Phase2 Data At Esmo Gi

Redx to Present Preclinical Data on RXC008 in an Oral Presentation at ECM Congress

Redx Pharma Provides Update on AIM Delisting

New major risk - Share price stability

Consensus EPS estimates upgraded to UK£0.062 loss

Recent updates

Redx Pharma Plc Reports Encouraging Zamaporvint (RXC004) Phase 2 Combination Data in MSS mCRC at ESMO GI Congress

Redx to Present Zamaporvint Phase2 Data At Esmo Gi

Redx to Present Preclinical Data on RXC008 in an Oral Presentation at ECM Congress

Redx Pharma Provides Update on AIM Delisting

New major risk - Share price stability

Consensus EPS estimates upgraded to UK£0.062 loss

Redx Announces That First Participant Dosed in Phase 1 Trial of RXC008

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Redx Pharma Plc, Annual General Meeting, Mar 14, 2024

New minor risk - Share price stability

New minor risk - Market cap size

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Redx Pharma Plc to Report Fiscal Year 2023 Results on Dec 15, 2023

New minor risk - Financial data availability

New minor risk - Shareholder dilution

Redx Pharma plc to Present Preclinical Data on RXC009, A Selective Discoidin Domain Receptor 1 Inhibitor

Redx Pharma Plc has completed a Follow-on Equity Offering in the amount of £14.059359 million.

Redx Pharma plc Appoints Joseph Anderson as Non-Executive Director

Redx Pharma Plc Announces Executive Changes

Does Redx Pharma (LON:REDX) Have A Healthy Balance Sheet?

Redx Pharma plc Zelasudil Receives FDA Orphan Drug Designation

New minor risk - Market cap size

Redx Pharma Plc Announces Directorate Changes

Is Redx Pharma (LON:REDX) Using Too Much Debt?

Price target decreased by 9.9% to UK£1.32

First half 2023 earnings released: UK£0.062 loss per share (vs UK£0.035 loss in 1H 2022)

Redx Pharma Plc's Discovery of Pirtobrutinib Recognised with Unveiling of Commemorative Plaque At Alderley Park

Redx Pharma Plc Presents Preclinical Efficacy Data for RXC007 Showing Significant Results in Cancer-Associated Fibrosis Models

Redx Pharma Plc to Report First Half, 2023 Results on May 17, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Redx Pharma Plc, Annual General Meeting, Mar 14, 2023

Redx Pharma Plc Provides Progress Updates on RXC007 Clinical Programme

Consensus revenue estimates increase by 15%, EPS downgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Redx Pharma Plc to Report Q4, 2022 Results on Dec 20, 2022

High number of new directors

Redx Pharma plc to Present on Potential of RXC007 in Fibrotic Diseases at Antifibrotic Drug Discovery Meeting

Redx Pharma plc Announces First Patient Dosed in Phase 2a Trial for RXC007

Bullish: Analysts Just Made A Significant Upgrade To Their Redx Pharma Plc (LON:REDX) Forecasts

Consensus revenue estimates increase by 24%

Consensus revenue estimates increase by 31%

Redx Pharma Announces Two Presentations Were Delivered at the Inaugural Extracellular Matrix Pharmacology Congress in Copenhagen, 23-25 June

First half 2022 earnings released

Redx Pharma Plc to Report Q2, 2022 Results on Jun 23, 2022

Redx Pharma Plc has completed a Follow-on Equity Offering in the amount of £34.261864 million.

Price target increased to UK£1.70

High number of new directors

Redx Pharma Plc Presents Encouraging RXC004 Preclinical Data

Redx Pharma plc Announces Nomination of Clinical Development Candidate

Redx Pharma Plc Announces Committee Changes

Redx Pharma Plc, Annual General Meeting, Mar 08, 2022

High number of new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

First half 2021 earnings released: UK£0.053 loss per share (vs UK£0.027 loss in 1H 2020)

Non-Executive Chairman Iain Ross has left the company

Redx Pharma Announces First Subject Dosed in Phase 1 Study with Lead Fibrosis Candidate RXC007, a ROCK2 Selective Inhibitor

Redx Pharma Announce Mead Will Step Down from the Board

Redx Pharma plc Announces Search for A US Based Chief Financial Officer Has Been Initiated

Chief Medical Officer has left the company

New 90-day high: UK£0.68